UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~October~~January ~~2024~~2025

Commission File Number: 001-38773

CHINA SXT PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

178 Taidong Rd North, Taizhou

Jiangsu, China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

~~Changes~~Resignation inof ~~Registrant’s Certifying Accountant~~Director

On ~~October 9~~January 20, ~~2024~~2025, Songfan He resigned from ~~the~~his ~~Company’s~~positions ~~audit~~as ~~committee~~an ~~and~~independent director of the board of directors ~~approved~~ (the ~~proposed~~“Board”) ~~appointment~~ of ~~Enrome~~China ~~LLP~~SXT Pharmaceuticals, Inc. (the “~~Enrome~~Company”), as the ~~Company’s~~chairman ~~independent~~of ~~registered~~the ~~public~~audit ~~accounting~~committee ~~firm~~(the ~~and~~“Audit ~~the~~Committee”), ~~dismissal~~a member of the ~~Company’s~~compensation ~~previous~~committee ~~independent~~(the ~~public~~“Compensation ~~accounting~~Committee”) ~~firm,~~and ZHnominating ~~CPA,~~& ~~LLC~~corporate governance committee (the “ZHNominating Committee”), oneffective immediately. Mr. He indicated that his resignation was due to personal reasons and was not the ~~same~~result ~~date~~of any disagreement with management of the Company or the Board.

ZHAppointment ~~served as the Company’s independent public accounting firm since January 14, 2018. During the Company’s engagement~~ of ZH until October 9, 2024, there were no disagreements between the Company and ZH on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of ZH, would have caused it to make reference to the subject matter of the disagreements in connection with its report on the Company’s consolidated financial statements for such period. During the two most recent fiscal years and through the subsequent interim period preceding the dismissal of ZH, there was none “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F.Director

~~During~~On ~~the~~January ~~two most recent fiscal years ended March 31~~20, 2024 and 2023 and any subsequent interim period prior to engaging Enrome neither the Company nor anyone on its behalf consulted Enrome regarding either (i) the application of accounting principles to any proposed or completed transaction2025, or the ~~type~~Board of ~~audit opinion that might be rendered on~~ the Company’s passed ~~financial statements, and neither~~ a ~~written~~resolution ~~report nor oral advice was provided~~ to ~~the~~appoint ~~Company~~Mr. ~~that~~Yong ~~Enrome~~Lip ~~concluded~~Chee ~~was~~as an ~~important~~independent ~~factor~~director ~~considered~~of by the ~~Company in reaching a decision as to any accounting~~Board, ~~auditing~~the orchairman ~~financial~~of ~~reporting issue; or (ii) any matter that was either~~ the ~~subject~~Audit ofCommittee, a ~~disagreement (as~~member ~~defined~~of inthe ~~Item~~Compensation ~~16F(a)(1)(iv) of~~Committee ~~Form 20-F~~ and the ~~related~~Nominating ~~instructions~~Committee, to ~~Item~~fill ~~16F~~in ofthe ~~Form 20-F)~~vacancies orresult afrom ~~reportable~~Mr. ~~event~~He’s resignation.

~~The~~Mr. ~~Company~~Yong ~~has~~Lip ~~provided~~Chee ZHhas ~~with~~ a ~~copy~~background ofin ~~the~~sales ~~disclosures~~and client relations within the ~~Company~~healthcare issector. ~~making~~Since in2021, ~~this~~Mr. ~~Current~~Yong ~~Report~~has been an independent sales consultant, advising healthcare companies on ~~Form 6-K~~market ~~and~~penetration ~~has~~strategies ~~filing~~and asdistributor ~~Exhibit 16~~partnerships.1 ~~the~~From ~~letter~~2017 ~~from~~to ZH2021, ~~stating~~he ZHserved ~~agrees~~as a sales supervisor at Winner Medical Hong orKong, ~~has~~where nohe ~~basis~~promotes medical consumables products to ~~agree~~hospitals orand ~~disagree~~private ~~with~~healthcare ~~the~~medical ~~disclosures~~professionals ~~made~~and ~~herein~~related users. He earned a bachelor’s degree in business administration from Universiti Malaya in Malaysia in 2013.

~~SUBMITTED~~Mr. ~~HEREWITH~~Yong Lip Chee entered into a director offer letter with the Company, which establishes certain terms and conditions governing his service to the Company. The form of director offer letter is qualified in its entirety by reference to the complete text of the form the employment agreement, which is filed hereto as Exhibit 99.2.

~~Exhibits:~~Appointment Co-Chief Executive Officer

16On January 20, 2025, the Board of the Company approved the appointment of Mr.1 ~~Letter~~Simon ~~from~~Lim ZHSze ~~CPA,~~Beng ~~LLC,~~as ~~dated~~the ~~October~~Co-Chief 12Executive Officer (the “Co-CEO”) of the Company with immediate effect. In connection with this appointment, ~~2024~~the title of Mr. Feng Zhou was changed from the Chief Executive Officer and Director to the Co-CEO and Director of the Company.

Mr. Simon Lim Sze Beng is an experienced professional in the healthcare sector. Since 2019, he has served as a manager of Reform Medical Marketing Co., Limited, where he serves clients in medical, and healthcare sectors and promotes their products and services. From 2017 to 2019, he was the senior operations director at Axcel Digital, where he conducts multichannel promotion for healthcare sector clients. He earned a bachelor’s degree in arts from Universiti Malaya in Malaysia in 2001.

Mr. Simon Lim Sze Beng entered into an employment agreement with the Company, which establishes certain terms and conditions governing his service to the Company. The form of the employment agreement is qualified in its entirety by reference to the complete text of the form the employment agreement, which is filed hereto as Exhibit 99.1.

Each of Mr. Yong and Mr. Beng does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K.

EXHIBIT INDEX

Exhibit No.		Description

99.1		Form of the Employment Agreement
99.2		Form of the Director Offer Letter

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: ~~October~~January 1523, ~~2024~~2025

China SXT Pharmaceuticals, Inc. By: /s/ Feng Zhou Name: Feng Zhou Title: Co-Chief Executive Officer

Filing Compare · China SXT Pharmaceuticals, Inc.